Tripep: Interim analysis of ChronSeal

STOCKHOLM, Sweden--(Business Wire)--
In the recently conducted interim analysis of the phase I/IIa study on the wound
healing product ChronSeal in which Tripep has a 10% ownership it was concluded
that the group of patients randomized for placebo treatment but receiving
standard of care at the time of the analysis was too small for allowing
statistical analysis. The trends that could be drawn were so encouraging that
the study will continue and thereby be expanded by 50% of the study population
size at the time of the interim analysis. Also so far the study has shown that
ChronSeal is safe and that no serious or unexpected side effects have been
reported. The final results are estimated to be obtained already during the
first quarter of 2010.

About Tripep

Tripep develops drugs against chronic disease based on proprietary and other
parties` patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal and a therapeutic
vaccine against Hepatitis C, named ChronVac-C, plus the RAS technology platform.
The Tripep share is admitted to trade on First North. Remium AB is Certified
Adviser for Tripep AB. For more information, please refer to the company`s
website: www.tripep.se.

In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take precedence.

This information was brought to you by Cision http://www.cisionwire.com

Tripep AB
Anders Vahlne, CEO & Head of Research
Tel: +46 8 5858 1313
Mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se

Copyright Business Wire 2009